View Older Stories View More Recent Stories

Mar 13, 2017 08:42AM Zealand hosts conference call on March 15 at 4 pm CET to present 2016 full-year results
Feb 8, 2017 01:49AM Zealand reports Q4 2016 Lyxumia® royalty revenue
Feb 7, 2017 08:12AM Notice of the date of Zealand's Annual General Meeting 2017 and of deadline for proposals for the agenda
Feb 6, 2017 09:26AM Patient recruitment completed for phase II trial with glepaglutide for treatment of short bowel syndrome
Jan 17, 2017 02:22PM EU approval of Suliqua(TM) triggers USD 10 million milestone payment to Zealand
Jan 4, 2017 02:15AM Zealand reports that Sanofi announces Soliqua(TM) 100/33 now available in the U.S
Dec 19, 2016 05:00AM Financial calendar for 2017
Dec 13, 2016 02:36AM Zealand initiates Phase IIa clinical trial with dasiglucagon in a dual-hormone artificial pancreas system from Beta Bionics
Nov 21, 2016 07:41PM The U.S. FDA approves Soliqua(TM) 100/33 for the treatment of adults with type 2 diabetes
Nov 11, 2016 07:53AM CHMP issues positive opinion recommending Suliqua(TM) (iGlarLixi) for approval in the EU
Nov 10, 2016 07:26AM Zealand presents at three international biotech/healthcare investor conferences in November and December 2016
Nov 9, 2016 01:33AM Zealand interim report for the first nine months of 2016 (unaudited)
Oct 28, 2016 09:56AM Notice of Zealand's interim report for the first nine months of 2016 and invitation to conference call
Sep 20, 2016 08:52AM Zealand sponsored educational symposium highlights the need for better medical treatment of short bowel syndrome
Aug 25, 2016 01:59AM Zealand's interim report for the first half of 2016 (unaudited)
May 4, 2016 02:04PM Helsinn Announces Top-Line Results of its Phase IIb Trial With Elsiglutide for the Prevention of Chemotherapy-induced Diarrhea in Colorectal Cancer Patients
Dec 23, 2015 01:17AM Zealand announces that Sanofi has submitted LixiLan for regulatory review in the US, triggering a USD 20 million milestone payment
Dec 18, 2015 09:58AM Zealand to present at 34th Annual J.P. Morgan Healthcare Conference on 14 January 2016
Dec 9, 2015 03:23AM Zealand presented on its dual acting peptides at the New York Academy of Sciences' meeting GLP-1 Treatment for Diabetes and Beyond
Dec 3, 2015 09:34AM Zealand strengthens its Senior Management team with the appointment of Carlos de Sousa as Chief Business Officer
Nov 5, 2015 03:35AM Zealand interim report for the first nine months of 2015 (un-audited): Financial results on target with significant pipeline progress
Nov 4, 2015 10:01AM Zealand is ready to take next steps in a diligent growth strategy for accelerated value creation: From peptide to patient
Oct 29, 2015 03:22AM Zealand reports Lyxumia(r) royalty revenue for Q3 2015 and that Sanofi confirms expected next steps in the US regulatory process
Oct 14, 2015 04:37AM Zealand to host Capital Markets Days in New York City and Copenhagen in November
Oct 9, 2015 02:08AM Zealand meets development milestone in collaboration with Boehringer Ingelheim
Sep 29, 2015 01:12AM Zealand informs that Sanofi's New Drug Application for lixisenatide (Lyxumia(R)) has been accepted for review by the FDA
Sep 17, 2015 02:10AM Zealand advances its proprietary, long-acting GLP-2 analogue, ZP1848, into clinical Phase II development for the treatment of Short Bowel Syndrome
Sep 15, 2015 07:37AM Zealand presents new preclinical data on its novel GIP peptide therapeutic, ZP-I-98, at the 51st EASD Annual Meeting
Sep 14, 2015 01:16AM Sanofi has announced the successful completion of LixiLan-L, the second pivotal Phase III trial with LixiLan to demonstrate positive results
Jul 30, 2015 04:28AM Major shareholder announcement
Jul 30, 2015 02:10AM Lixisenatide (Lyxumia(R)) royalty revenue increased in Q2 2015 as Sanofi confirms the submission of a NDA in the US
Jul 29, 2015 02:30AM CORRECTION: Sanofi has announced that the first LixiLan Phase III trial, LixiLan-O, met primary study endpoint
Jul 29, 2015 02:01AM Sanofi has announced that the first LixiLan Phase III trial, LixiLan-O, met primary study endpoint
Jun 26, 2015 02:17AM Phase I trial results for Zealand's glucagon analogue, ZP4207 support its further development as a ready-to-use rescue treatment for severe hypoglycemia in diabetes patients on insulin therapy
Jun 12, 2015 12:03PM Major Shareholder Announcement
Jun 9, 2015 10:50AM Zealand informs of updates given by Sanofi on Lyxumia(r) and LixiLan on an IR Thematic Conference Call on Diabetes
Jun 8, 2015 02:21PM Zealand informs that data presented from the ELIXA study establish Lyxumia(r) as the first GLP-1 receptor agonist with cardiovascular safety proven in a long-term outcome trial
Jun 6, 2015 12:58PM Presentations on two novel Zealand preclinical peptide therapeutics as possible approaches for the treatment of Type 2 diabetes and obesity at the American Diabetes Association's (ADA) 74th Scien
Jun 6, 2015 12:23PM Zealand announces that Sanofi has informed of results from GetGoal Duo-2, showing advantages of Lyxumia(r) versus rapid-acting insulin as add-on to Lantus(r) for the treatment of Type 2 diabetes
Jun 2, 2015 09:51AM Zealand Increases the Share Capital After Exercise of Employee Warrants and Announces an Amendment to Its Articles of Association
Jun 2, 2015 05:30AM New data on lixisenatide (Lyxumia(r)) including ELIXA results on LixiLan, and on novel Zealand peptide therapeutics, to be presented at the American Diabetes Association's (ADA) 75th Scientific S
May 29, 2015 08:09AM Zealand Presents to Investors at Four Conferences in June 2015
May 22, 2015 01:41AM Zealand Interim Report for Q1 2015 (unaudited) Increase in royalty revenue and progression of the development pipeline
May 20, 2015 01:33AM Zealand starts clinical development of a multiple-dose version of its stable glucagon analogue, ZP4207
May 4, 2015 03:03AM Zealand gives three presentations at the American TIDES 2015 conference - including as keynote speaker
Apr 30, 2015 01:41AM Zealand reports Lyxumia(r) royalty revenue for Q1 2015
Mar 19, 2015 04:28AM Zealand Announces Organizational and Management Changes
Mar 19, 2015 02:17AM Zealand announces that Sanofi has published top-line results from the ELIXA cardiovascular safety outcomes study of Lyxumia(r) (lix-isenatide)
Mar 13, 2015 02:55AM Zealand announces Full Year results in line with guidance and publication of the Annual Report for 2014
View More Recent Stories View Older Stories